光学相干断层成像指导准分子激光联合药物涂层球囊治疗复发性支架内再狭窄的初步研究Preliminary study of excimer laser coronary atherectomy combined with drug-coated balloon in the treatment of recurrent in-stent restenosis guided by optical coherence tomography
王宁远,冯欢欢,王威,赖图雅,辛倩,郭军,陈韬,汪奇,高磊
摘要(Abstract):
目的 观察准分子激光冠状动脉斑块消蚀术(ELCA)联合药物涂层球囊(DCB治疗复发性支架内再狭窄(R-ISR)的安全性和有效性。方法 回顾性分析2021年9月至2022年9月在中国人民解放军总医院第六医学中心心血管医学部行光学相干断层成像(OCT)辅助下ELCA联合DCB治疗的R-ISR患者9例,导丝通过病变后应用OCT评估病变特征,ELCA治疗后选择DCB处理,随后再次行OCT检查评估。观察手术成功率及并发症发生情况,随访有无主要不良心血管事件(MACE)发生。结果 纳入9例患者共9处靶病变,平均年龄(64.6±12.8)岁,男8例(8/9)。所有患者均选用1.4 mm激光消蚀导管,均成功完成手术。术后未发生冠状动脉穿孔、严重夹层、冠状动脉慢血流或无复流等。随访6个月未发生MACE。1例(1/9)存在支架膨胀不全,9例(9/9)均合并新生内膜增殖,其中6例(6/9)表现为均质性,1例(1/9)为分层性,2例(2/9)为异质性,未发现钙化斑块或支架贴壁不良。术后新生内膜面积[(1.58±0.67)mm~2比(3.00±1.07)mm~2,P=0.002]、新生内膜负荷[(25.10±8.60)%比(58.50±19.00)%,P<0.001]均显著低于术前,差异均有统计学意义。术后最小管腔直径[(2.13±0.23)mm比(1.36±0.29)mm,P<0.001]、最小管腔面积[(4.70±0.98)mm~2比(2.08±0.93)mm~2,P<0.001]均显著高于术前,差异均有统计学意义。结论 初步研究表明OCT指导ELCA联合DCB治疗R-ISR安全、有效。
关键词(KeyWords): 复发性支架内再狭窄;光学相干断层成像;准分子激光冠状动脉斑块消蚀术;药物涂层球囊
基金项目(Foundation): 国家自然科学基金项目(81970443)
作者(Author): 王宁远,冯欢欢,王威,赖图雅,辛倩,郭军,陈韬,汪奇,高磊
参考文献(References):
- [1] Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis[J]. J Am Coll Cardiol,2014,63(24):2659-2673. DOI:10.1016/j.jacc.2014.02.545.
- [2] Alfonso F, Coughlan JJ, Giacoppo D, et al. Management of in-stent restenosis[J]. EuroIntervention, 2022, 18(2):e103-e123. DOI:10.4244/EIJ-D-21-01034.
- [3] Giustino G, Colombo A, Camaj A, et al. Coronaryin-stent restenosis:JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 80(4):348-372. DOI:10.1016/j.jacc.2022.05.017.
- [4] Cassese S, Xu B, Habara S, et al. Incidence and predictors of reCurrent restenosis after drug-coated balloon angioplasty for restenosis of a drug-eluting stent:the ICARUS cooperation[J].Rev Esp Cardiol(Engl Ed), 2018, 71(8):620-627.DOI:10.1016/j.rec.2017.08.005.
- [5] Singh AD, Singal AK, Mian A, et al. Recurrent drugeluting stent in-stent restenosis:a state-of-the-art review of pathophysiology, diagnosis, and management[J].Cardiovasc Revasc Med, 2020, 21(9):1157-1163.DOI:10.1016/j.carrev.2020.01.005.
- [6] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2):87-165. DOI:10.1093/eurheartj/ehy394.
- [7] Alfonso F, Rivero F, Cortese B. Excimer laser prior to drugcoated balloon treatment of in-stent restenosis[J]. Int J Cardiol,2022, 348:47-49. DOI:10.1016/j.ijcard.2021.11.082.
- [8] Miyazaki T, Ashikaga T, Fukushima T, et al. Treatment of in-stent restenosis by excimer laser coronary atherectomy and drug-coated balloon:serial assessment with optical coherence tomography[J]. J Interv Cardiol, 2019, 2019:6515129.DOI:10.1155/2019/6515129.
- [9]《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志,2016,24(2):61-67. DOI:10.3969/j.issn.1004-8812.2016.02.001.
- [10]马越,宋雷,黄云飞,等.反复支架内再狭窄的光学相干断层成像病变特征分析[J].中国循环杂志,2022, 37(2):129-135. DOI:10.3969/j.issn.1000-3614.2022.02.004.
- [11] Shimono H, Kajiya T, Takaoka J, et al. Characteristics of recurrent in-stent restenosis after second-and third-generation drug-eluting stent implantation[J]. Coron Artery Dis, 2021,32(1):36-41. DOI:10.1097/MCA.0000000000000945.
- [12]杨丽霞,周玉杰,王志坚,等.联合应用准分子激光冠状动脉斑块消融术和药物涂层球囊治疗冠状动脉支架内再狭窄的观察性研究[J].中国医药,2020, 15(8):1174-1177.DOI:10.3760/j.issn.1673-4777.2020.08.006.
- [13]管浩,王天杰,乔树宾.准分子激光成功治疗右冠状动脉支架内反复再狭窄旋磨失败病变一例[J].中国循环杂志,2021,36(8):822-824. DOI:10.3969/j.issn.1000-3614.2021.08.015.
- [14]刘韵情,荆全民,王耿,等.准分子激光冠状动脉消蚀术治疗冠状动脉支架内再狭窄临床效果观察[J].临床军医杂志,2021, 49(5):553-554. DOI:10.16680/j.1671-3826.2021.05.22.
- [15]李辉,夏博,米秀青,等.准分子激光消蚀术在支架内再狭窄病变中的应用[J].中国介入心脏病学杂志,2020, 28(8):425-429. DOI:10.3969/j.issn.1004-8812.2020.08.002.
- [16] Ichimoto E, Kadohira T, Nakayama T, et al. Long-term clinical outcomes after treatment with excimer laser coronary atherectomy for in-stent restenosis of drug-eluting stent[J].Int Heart J, 2018, 59(1):14-20. DOI:10.1536/ihj.16-638.
- [17]王兴旭,张奇.准分子激光冠状动脉斑块消融术治疗进展[J].中国介入心脏病学杂志,2020, 28(10):594-596. DOI:10.3969/j.issn.1004-8812.2020.10.011.
- [18] Cremers B, Toner JL, Schwartz LB, et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter[J]. Clin Res Cardiol, 2012, 101(6):469-476.DOI:10.1007/s00392-012-0415-7.
- [19] Ishihara T, Dohi T, Nakamura D, et al. Impact of in-stent tissue characteristics on excimer laser coronary angioplasty prior to drug-coated balloon treatment[J]. Int J Cardiol, 2021,339:28-32. DOI:10.1016/j.ijcard.2021.07.019.